KMPH News and Press, KemPharm Inc From 12/20/21

KemPharm (NASDAQ:KMPH) board has authorized a share repurchase program to up to $50M of the company’s outstanding stock. The share repurchase authorization is effective immediately and valid through December 31, 2023. Represents equivalent to approximately 18 percent of KemPh...

CELEBRATION, Fla., Dec. 20, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today its Board of Directors has authorized a program to repurchase up to $50 million of ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Kempharm (NASDAQ:KMPH) has been added to the NASDAQ Biotechnology Index, effective prior to market open on December 20, 2021. Companies in the Nasdaq Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as ...

Data reveal serdexmethylphenidate (SDX) delivered at doses higher than those studied with AZSTARYS ® is well-tolerated, yields dose-proportional d-MPH exposure, and produces targeted biological effects CELEBRATION, Fla., Dec. 14, 2021 (GLOBE NEWSWIRE) -- KemPharm,...

CELEBRATION, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced its common stock has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI) i...

CELEBRATION, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it has been named the 2021 David J. Gury Company of the Year by BioFlorida. The ...

KemPharm, Inc. (KMPH) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Jason Rando – Tiberend Strategic Advisors Travis Mickle – President and Chief Executive Officer LaDuane Clifton – Chief Financial Officer Rich Pascoe – Executiv...

KemPharm (NASDAQ:KMPH): Q3 GAAP EPS of -$0.06 beats by $0.02. Revenue of $1.97M (+3.7% Y/Y) misses by $0.18M. Press Release For further details see: KemPharm EPS beats by $0.02, misses on revenue

Lead Independent Director Richard W. Pascoe Named Executive Chairman Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 10, 2021, 4:30 p.m. ET Corporate and Regulatory Highlights Appointment of Richard W. Pascoe as Execut...